On September 17, 2026, Lisata Therapeutics completed its acquisition of Marea Therapeutics via a stock-for-stock merger. Former Marea shareholders received approximately 1.79 million shares of common stock and 211,365 shares of Series C Non-Voting Convertible Preferred Stock. Concurrently, Lisata raised $225 million in a private placement by issuing 150,868 shares of Series C Preferred Stock to institutional investors. Post-transaction ownership is projected at approximately 59.54% for former Marea equityholders and 38.07% for new investors. Ted W. Love was appointed to the Board, and Josh Lehrer became President and Chief Operating Officer. Lisata Therapeutics operates in the clinical-stage pharmaceutical industry.
